Physician profile
Grace L Federman
NPI 1033160924
$10,499.31
in general payments reported to CMS, 2019-2025
35 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $895 · 2021: $1,414 · 2022: $1,832 · 2023: $1,653 · 2024: $2,033 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,958 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,958.39 |
| Education | $109.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,970.91 | 2019-2025 | |
| Janssen Biotech, INC. | $849.96 | 2019-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $798.04 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Pfizer INC. | $791.61 | 2019-2025 | |
| Leo Pharma INC. | $758.57 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $716.02 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Incyte Corporation | $449.30 | 2021-2025 | Opzelura |
| Ucb, INC. | $422.47 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $414.99 | 2019-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $392.30 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $382.16 | 2019-2024 | |
| Genzyme Corporation | $335.87 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.21 | 2019-2024 | Dupixent |
| Galderma Laboratories, L.P. | $288.89 | 2019-2025 | Nemluvio, Dysport |
| Merz North America, INC. | $221.38 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $202.85 | 2023-2024 | Zoryve |
| Epi Health, LLC | $181.23 | 2021-2022 | |
| Allergan, INC. | $166.35 | 2019-2022 | |
| Dermavant Sciences, INC. | $127.32 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $113.87 | 2023-2024 | Sotyktu |
| Organon LLC | $90.35 | 2025 | Vtama |
| Biofrontera INC. | $69.98 | 2019 | |
| Almirall LLC | $64.11 | 2024 | Seysara |
| Medtronic Vascular, INC. | $63.67 | 2019 | |
| Hydrofera LLC | $50.78 | 2024 | Hydrofera Blue |
| Vyne Pharmaceuticals INC. | $50.01 | 2020 | |
| Mayne Pharma Commercial LLC | $46.45 | 2019-2021 | |
| Dermira, INC. | $44.68 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $35.40 | 2022 | |
| Verrica Pharmaceuticals INC. | $18.86 | 2023 | Ycanth |
| Journey Medical Corporation | $18.00 | 2022 | |
| Fresenius Kabi USA, LLC | $17.20 | 2023 | |
| Sandoz INC. | $17.00 | 2025 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2023 | Spevigo |
| Mission Pharmacal Company | $13.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Federman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.